Home >> News >>News Center >> Official Announcement | NeoCura Completed the Series A + Financing of RMB 500 Million Yuan to Accelerate the R&D of AI+RNA Drugs
Details

Official Announcement | NeoCura Completed the Series A + Financing of RMB 500 Million Yuan to Accelerate the R&D of AI+RNA Drugs

On December 21, 2021, NeoCura Bio-Medical Technology Co., Ltd (¡°NeoCura¡±) announced the completion of the A+ round financing of RMB 500 Million Yuan. This round of financing was jointly led by PICC Capital and Mr. Zhou Yahui, a famous investor, and managed by Shunxi Fund under Beijing State-owned Capital Operation and Management Co., Ltd., Jiayin Fund, CDH Investment and con-invested by the existed shareholders, continuously arranged for the area of RNA innovative medicine.

This round of financing will be used to advance the research and development progress of pipeline under development such as mRNA-based tumor neoantigen vaccine, tumor microenvironment immunomodulator and virus vaccine of NeoCura. Meanwhile, NeoCura will successively optimize the AI (artificial intelligence) platform, improve the construction of RNA drug research and production site, and accelerate the clinical and commercial process of tumor innovative drugs.

"As a cutting-edge technology in the world, RNA has a very broad application prospect and is also one of my key layouts", said Zhou Yahui, co-founder and chairman of NeoCura. With strong scientific research team, world-leading AI algorithm and multiple independent intellectual property rights, NeoCura is highly competitive among similar domestic enterprises. I have pinned high hopes on its pipeline under development, and expect that NeoCura can push mRNA, a hot new technology, into clinical application as soon as possible, and usher in a new era of tumor immunotherapy.

Shu Wanting, head of the investment department of PICC Equity Company, said:" PICC Equity is full of confidence in the future of NeoCura. We hope that NeoCura will take advantage of the situation and make persistent efforts under the leadership of Dr. Wang Yi, to successfully apply mRNA technology to the field of tumor therapy. We hope that the application of emerging technologies can overcome the bottleneck of existing immunotherapy in the treatment of solid tumors and present more breakthroughs and innovations in the treatment of critical diseases, so as to make outstanding contributions to the health of the whole people together with PICC."

Ren Peng, head of Shunxi Fund under Beijing State-owned Capital Operation and Management Co., Ltd., said: "Due to the advanced nature of its principles, mRNA technology will have great social and commercial value in both the prevention field and the disease treatment field. mRNA technology has been accelerated due to the spread of COVID-19 but will not die out with the disappearance of the COVID-19. Shunxi Fund believes that NeoCura has the capability to develop mRNA technology into tumor therapy, protein supplement therapy and other fields in the future, and contribute to disease prevention and clinical treatment."

Wang Tie, General Manager of Jiayin Fund, said: "The selection of NeoCura is the result of careful research on the domestic RNA industry. First of all, it is optimistic about the broad prospect of RNA in the future. The direction that the NeoCura uses the neoantigen to make a specific tumor vaccine meets the development requirements of medicine in the future and can form a tumor drug technology platform with full scalability. At the same time, we are very optimistic about the team of scientists led by Dr. Wang Yi and believe that NeoCura will definitely become one of leading enterprises in the field of RNA innovative drugs in China and make great contributions for China to catch up with and surpass the advanced world level in the field of tumor immunotherapy."

Dr. Liu Dan, partner of CDH Innovation and Growth Fund, said: "NeoCura has a good team and technical reserve in the design of tumor neoantigens and drugs based on RNA platform. With the encouraged research and development progress, we look forward to the clinical manifestation of its research and development pipeline in this field."

Dr. Wang Yi, co-founder &CEO of NeoCura, said: "Thank you very much for your recognition and support. This round of financing has consolidated the R&D backing of NeoCura and formed a strong guarantee for accelerating the progress of pipeline under research. As a high-tech enterprise focusing on the field of RNA innovative drugs, NeoCura will continue to deeply explore the research and development of RNA drugs, expecting to fill the unsatisfied clinical needs through the application of emerging technologies. We look forward to the early launch of the products under development to benefit cancer patients around the world. "

1639972405166481.jpg

Founded in 2017, NeoCura features with AI-empowered RNA drugs, and is committed to becoming one of the international leading research and development enterprises of RNA innovative drugs. A multi-omics big data collection platform and a multi-microbiome database have been set up. AI and biological information technology have been used for deep drug target mining and automatic drug design for innovative RNA drug research.

The company has gathered top-level scientific research teams with global vision, including dozens of Ph.D./postdoctoral students from Harvard, Cambridge, Cornell, Peking University, Tsinghua, Chinese Academy of Sciences and other prestigious universities, and has experts in various fields such as AI and biological information technology, tumor immunity, research and development of new vaccines, drug delivery, nucleic acid carriers, etc. The pipeline under research covers multiple directions such as tumor neoantigen vaccine, tumor microenvironment immune regulator, virus vaccine, etc., and has established a leading RNA drug production center in China to support pipeline research and development and clinical requirements.

NeoCura has independently developed the AI and biological information technology-based target mining platform, RNA drug platform, fully automatic drug design platform, multi-omics big data collection and analysis platform and drug screening and verification platform, aiming at promoting RNA drug research by combining artificial intelligence algorithm with real-world data verification. NeoCuraTM AI ALPINE tumor neoantigen prediction system with its own independent R&D property has the highest prediction accuracy in the world.

With its leading AI technology, powerful R&D pipeline and excellent innovation capability, NeoCura has successively won "2021 China's Most Potential Enterprise" and "2021 TOP10 China AI/ Computing Pharmaceutical Innovation Enterprises ".

About Mr. Zhou Yahui:

Mr. Zhou Yahui is the founder, former chairman and CEO of Kunlun Wanwei, a listed A-share company; a famous investor in China's scientific and technological innovation field ranked 19th in the latest TOP 50 Venture Capitalists in China in 2021; at the same time, he is also the incubator and co-founder of NeoCura.

About the PICC Health Pension Industry Investment Fund£º

The PICC Health Pension Industry Investment Fund is an insurance private equity investment fund focusing on medical health, which is managed by PICC Capital Equity Investment Company Ltd. The scale of the first phase is RMB 3 billion yuan. Insisting on the investment philosophy of "research-driven, insight into the future, leading change", PICC Capital Equity Investment Company Ltd. recognizes innovation with in-depth research, discovers value with forward-looking vision, leads change with influential investment, focusing on clinical needs and good new technologies and striving to meet people's yearning for a better life.

About Shunxi Fund under Beijing State-owned Capital Operation and Management Co., Ltd.:

Beijing Shunxi Equity Investment Fund Management Co., Ltd. (hereinafter referred to as Shunxi Management Company) is a subsidiary of Beijing State-owned Capital Operation and Management Co., Ltd. (hereinafter referred to as BSCOMC) and also a venture capital platform of BSCOMC. Shunxi Management Company adheres to the functional orientation of venture capital platform, focusing on early investment and small investment, focusing on scientific and technological innovation and investment in early high-quality projects in medical and health fields, creating a market-oriented operation and management mechanism, and striving to become a first-class venture capital platform in China.

About Jiayin Fund:

Shenzhen Jiayin Fund Management Co., Ltd. is an equity investment platform under Hezheng Group. As a new force in the field of private equity investment in China, Shenzhen Jiayin Fund Management Co., Ltd. specializes in strengthening and building a first-class innovative investment field in China. Its key investment fields include biomedicine, new materials, semiconductors, high-end equipment manufacturing and other fields with high-tech, high added value and high growth.

About CDH Investment:

CDH Investment, founded in 2002, is one of the most influential alternative asset management institutions in China. Up to now, the management fund has reached RMB 170 billion yuan. CDH Investment has six business segments including private equity investment, Venture and Growth Capital (VGC), securities investment, real estate investment, mezzanine investment and wealth management. CDH has successively invested in more than 200 enterprises, more than 70 of which are listed at home and abroad, and cultivated a number of industry leading brands. The core idea of CDH Investment is to advance with the strugglers and create long-term value. CDH Investment is committed to becoming a long-term partner for global investors to explore the best investment opportunities, a partner for invested enterprises to create long-term value and an accelerator for China's industrial transformation and improvement of people's quality of life.





Scan ¡°code¡± to follow us on WeChat

NeoCura Bio-Medical Technology Co., Ltd.

Beijing: 3/F, Building 1,20 Life Science Park Road, Life Science Park,Changping District, Beijing





Website£ºwww.neocura.com.cn

E-mail£ºinfo@neocura.net

             bd@neocura.net

             pr@neocura.net

Tel£º+86 10 80766127




Guangzhou: 10/F, Block B, No. 388 Lianyun Road, Huangpu District, Guangzhou, China





Shenzhen: 12/F, Block B, Building 1, Yinxingzhijie Phase II, Longhua District, Shenzhen, China

Address:

  • Telephone

    • 010-80766127
  • ΢ÐÅɨһɨ

seo seo